Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern NashanKlinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, GermanyAbstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical tria...
Guardado en:
Autores principales: | Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e03be2da5bdf40568c482564d4475e36 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of basiliximab in the evolving renal transplantation immunosuppression protocol
por: Paola Salis, et al.
Publicado: (2008) -
Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation
por: Jacobo López-Abente, et al.
Publicado: (2021) -
Historical Overview of Vascular Allograft Transplantation
por: Kerbi Alejandro Guevara-Noriega, et al.
Publicado: (2019) -
Synergistic impact of pre-sensitization and delayed graft function on allograft rejection in deceased donor kidney transplantation
por: Hanbi Lee, et al.
Publicado: (2021) -
Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients
por: Thomas Duflot, et al.
Publicado: (2021)